Literature DB >> 22252965

Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.

Lucia Hernandez1,2, Paul M Wilkerson1, Maryou B Lambros1, Adriana Campion-Flora1, Daniel Nava Rodrigues1, Arnaud Gauthier1,3, Cecilia Cabral1, Vidya Pawar1, Alan Mackay1, Roger A'Hern4, Caterina Marchiò5, Jose Palacios6, Rachael Natrajan1, Britta Weigelt1,7, Jorge S Reis-Filho1.   

Abstract

The mechanisms underlying the progression from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) of the breast are yet to be fully elucidated. Several hypotheses have been put forward to explain the progression from DCIS to IDC, including the selection of a subpopulation of cancer cells with specific genetic aberrations, and the acquisition of new genetic aberrations or non-genetic mechanisms mediated by the tumour microenvironment. To determine whether synchronously diagnosed ipsilateral DCI and IDCs have modal populations with distinct repertoires of gene copy number aberrations and mutations in common oncogenes, matched frozen samples of DCIS and IDC were retrieved from 13 patients and subjected to microarray-based comparative genomic hybridization (aCGH) and Sequenom MassARRAY (Oncocarta v 1.0 panel). Fluorescence in situ hybridization and Sanger sequencing were employed to validate the aCGH and Sequenom findings, respectively. Although the genomic profiles of matched DCI and IDCs were similar, in three of 13 matched pairs amplification of distinct loci (ie 1q41, 2q24.2, 6q22.31, 7q11.21, 8q21.2 and 9p13.3) was either restricted to, or more prevalent in, the modal population of cancer cells of one of the components. Sequenom MassARRAY identified PIK3CA mutations restricted to the DCIS component in two cases, and in a third case the frequency of the PIK3CA mutant allele reduced from 49% in the DCIS to 25% in the IDC component. Despite the genomic similarities between synchronous DCIS and IDC, our data provide strong circumstantial evidence to suggest that in some cases the progression from DCIS to IDC is driven by the selection of non-modal clones that harbour a specific repertoire of genetic aberrations.
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22252965      PMCID: PMC4975517          DOI: 10.1002/path.3990

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  51 in total

1.  Resolving the resolution of array CGH.

Authors:  Bradley P Coe; Bauke Ylstra; Beatriz Carvalho; Gerrit A Meijer; Calum Macaulay; Wan L Lam
Journal:  Genomics       Date:  2007-02-02       Impact factor: 5.736

2.  Phosphoinositide 3-kinase mutations in breast cancer: a "good" activating mutation?

Authors:  Serena Di Cosimo; José Baselga
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

3.  PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.

Authors:  Kevin Kalinsky; Adriana Heguy; Umeshkumar K Bhanot; Sujata Patil; Mary Ellen Moynahan
Journal:  Breast Cancer Res Treat       Date:  2011-05-27       Impact factor: 4.872

4.  Distinct epigenetic changes in the stromal cells of breast cancers.

Authors:  Min Hu; Jun Yao; Li Cai; Kurt E Bachman; Frédéric van den Brûle; Victor Velculescu; Kornelia Polyak
Journal:  Nat Genet       Date:  2005-07-10       Impact factor: 38.330

5.  Regulation of in situ to invasive breast carcinoma transition.

Authors:  Min Hu; Jun Yao; Danielle K Carroll; Stanislawa Weremowicz; Haiyan Chen; Daniel Carrasco; Andrea Richardson; Shelia Violette; Tatiana Nikolskaya; Yuri Nikolsky; Erica L Bauerlein; William C Hahn; Rebecca S Gelman; Craig Allred; Mina J Bissell; Stuart Schnitt; Kornelia Polyak
Journal:  Cancer Cell       Date:  2008-05       Impact factor: 31.743

6.  Inferring tumor progression from genomic heterogeneity.

Authors:  Nicholas Navin; Alexander Krasnitz; Linda Rodgers; Kerry Cook; Jennifer Meth; Jude Kendall; Michael Riggs; Yvonne Eberling; Jennifer Troge; Vladimir Grubor; Dan Levy; Pär Lundin; Susanne Månér; Anders Zetterberg; James Hicks; Michael Wigler
Journal:  Genome Res       Date:  2009-11-10       Impact factor: 9.043

7.  Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast.

Authors:  Anne Vincent-Salomon; Carlo Lucchesi; Nadège Gruel; Virginie Raynal; Gaëlle Pierron; Rémi Goudefroye; Fabien Reyal; François Radvanyi; Rémy Salmon; Jean-Paul Thiery; Xavier Sastre-Garau; Brigitte Sigal-Zafrani; Alain Fourquet; Olivier Delattre
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

8.  Matrix crosslinking forces tumor progression by enhancing integrin signaling.

Authors:  Kandice R Levental; Hongmei Yu; Laura Kass; Johnathon N Lakins; Mikala Egeblad; Janine T Erler; Sheri F T Fong; Katalin Csiszar; Amato Giaccia; Wolfgang Weninger; Mitsuo Yamauchi; David L Gasser; Valerie M Weaver
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

9.  Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution.

Authors:  Sohrab P Shah; Ryan D Morin; Jaswinder Khattra; Leah Prentice; Trevor Pugh; Angela Burleigh; Allen Delaney; Karen Gelmon; Ryan Guliany; Janine Senz; Christian Steidl; Robert A Holt; Steven Jones; Mark Sun; Gillian Leung; Richard Moore; Tesa Severson; Greg A Taylor; Andrew E Teschendorff; Kane Tse; Gulisa Turashvili; Richard Varhol; René L Warren; Peter Watson; Yongjun Zhao; Carlos Caldas; David Huntsman; Martin Hirst; Marco A Marra; Samuel Aparicio
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962

10.  Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas.

Authors:  Felipe C Geyer; Britta Weigelt; Rachael Natrajan; Maryou B K Lambros; Dario de Biase; Radost Vatcheva; Kay Savage; Alan Mackay; Alan Ashworth; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2010-04       Impact factor: 7.996

View more
  67 in total

1.  High-resolution genomic profiling of thyroid lesions uncovers preferential copy number gains affecting mitochondrial biogenesis loci in the oncocytic variants.

Authors:  Ivana Kurelac; Dario de Biase; Claudia Calabrese; Claudio Ceccarelli; Charlotte Ky Ng; Raymond Lim; Alan MacKay; Britta Weigelt; Anna Maria Porcelli; Jorge S Reis-Filho; Giovanni Tallini; Giuseppe Gasparre
Journal:  Am J Cancer Res       Date:  2015-05-15       Impact factor: 6.166

2.  Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing.

Authors:  Anna K Casasent; Aislyn Schalck; Ruli Gao; Emi Sei; Annalyssa Long; William Pangburn; Tod Casasent; Funda Meric-Bernstam; Mary E Edgerton; Nicholas E Navin
Journal:  Cell       Date:  2018-01-04       Impact factor: 41.582

3.  PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.

Authors:  Rita A Sakr; Britta Weigelt; Sarat Chandarlapaty; Victor P Andrade; Elena Guerini-Rocco; Dilip Giri; Charlotte K Y Ng; Catherine F Cowell; Neal Rosen; Jorge S Reis-Filho; Tari A King
Journal:  Clin Cancer Res       Date:  2014-03-14       Impact factor: 12.531

4.  Recurrent inflammatory myofibroblastic tumors harboring PIK3CA and KIT mutations.

Authors:  Cheng-Fang Li; Chun-Xia Liu; Bing-Cheng Li; Yao-Yuan Shen; Xiao-Bin Cui; Wei Liu; Hong-Chao Dong; Li-Juan Pang; Wei-Hua Liang; Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

Review 5.  Controversies in the Treatment of Ductal Carcinoma in Situ.

Authors:  Andrea V Barrio; Kimberly J Van Zee
Journal:  Annu Rev Med       Date:  2017-01-14       Impact factor: 13.739

Review 6.  Functional Role of miRNAs in the Progression of Breast Ductal Carcinoma in Situ.

Authors:  Bethany N Hannafon; Wei-Qun Ding
Journal:  Am J Pathol       Date:  2018-09-29       Impact factor: 4.307

7.  Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.

Authors:  Kathleen Lambein; Mieke Van Bockstal; Lies Vandemaele; Rudy Van den Broecke; Veronique Cocquyt; Sofie Geenen; Hannelore Denys; Louis Libbrecht
Journal:  Virchows Arch       Date:  2017-05-31       Impact factor: 4.064

8.  Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity.

Authors:  Vanessa Almendro; Yu-Kang Cheng; Amanda Randles; Shalev Itzkovitz; Andriy Marusyk; Elisabet Ametller; Xavier Gonzalez-Farre; Montse Muñoz; Hege G Russnes; Aslaug Helland; Inga H Rye; Anne-Lise Borresen-Dale; Reo Maruyama; Alexander van Oudenaarden; Mitchell Dowsett; Robin L Jones; Jorge Reis-Filho; Pere Gascon; Mithat Gönen; Franziska Michor; Kornelia Polyak
Journal:  Cell Rep       Date:  2014-01-23       Impact factor: 9.423

9.  Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression.

Authors:  Kerstin Heselmeyer-Haddad; Lissa Y Berroa Garcia; Amanda Bradley; Clarymar Ortiz-Melendez; Woei-Jyh Lee; Rebecca Christensen; Sheila A Prindiville; Kathleen A Calzone; Peter W Soballe; Yue Hu; Salim A Chowdhury; Russell Schwartz; Alejandro A Schäffer; Thomas Ried
Journal:  Am J Pathol       Date:  2012-10-08       Impact factor: 4.307

10.  Copy number analysis of ductal carcinoma in situ with and without recurrence.

Authors:  Kylie L Gorringe; Sally M Hunter; Jia-Min Pang; Ken Opeskin; Prue Hill; Simone M Rowley; David Y H Choong; Ella R Thompson; Alexander Dobrovic; Stephen B Fox; G Bruce Mann; Ian G Campbell
Journal:  Mod Pathol       Date:  2015-06-19       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.